Alexander Menzies

Alexander Menzies has pioneered circulating tumor DNA monitoring as a strategy for guiding adjuvant therapy decisions and predicting relapse risk in patients with resected high-risk melanoma. His research has characterized ctDNA dynamics during adjuvant immunotherapy and targeted therapy, demonstrating that ctDNA clearance and conversion from detectable to undetectable correlate with improved recurrence-free survival. He has investigated tumor heterogeneity and acquired resistance mechanisms in patients progressing on BRAF/MEK inhibitors, exploring re-challenge strategies and sequencing approaches. His clinical research integrates molecular residual disease monitoring with contemporary melanoma treatment paradigms to optimize individualized care.